REVEALED: Invitae | Vintage Vibes

Invitae's Court-Approved Bankruptcy Sale Set for Five Months

Invitae, a leading medical genetics company, has received court approval for a five-month bankruptcy sale. The sale process will allow Invitae to repay its...

Top News · Feb 15, 2024

Vital medical tests evade regulation

Money and lobbying help shield lab-developed tests, including prenatal screenings, from heightened federal scrutiny

Salon · Jan 25, 2023

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022

Upgrades

Benzinga · Jul 26, 2022

Invitae Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q1, Invitae (NYSE:NVTA) posted sales of $123.69 million. Earnings were up 11.34%, but Invitae still reported an overall loss of $181.86 million.

Benzinga · May 13, 2022

Analyst Ratings for Invitae

Analysts have provided the following ratings for Invitae (NYSE:NVTA) within the last quarter:

Benzinga · May 4, 2022

Is Invitae Stock a Buy Under $5?

Invitae's (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around the stock. However, given the company's widening losses and poor profitability, the question is, is it worth betting on the stock at the…

StockNews.com · May 4, 2022

Recap: Invitae Q1 Earnings

Invitae (NYSE:NVTA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Invitae missed estimated earnings by 2.63%, reporting an EPS of $-0.78 versus an estimate of $-0.76.

Benzinga · May 3, 2022

Expert Ratings for Invitae

Over the past 3 months, 4 analysts have published their opinion on Invitae (NYSE:NVTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Apr 18, 2022

Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation

Invitae Corp's (NASDAQ: NVTA) 

Benzinga · Feb 25, 2022